Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 105

Spire Global spies reverse takeover opportunity

The Qualcomm, Qihoo 360, Mitsui and Itochu-backed space data provider will be valued at $1.6bn and listed on the New York Stock Exchange once the merger closes.

Mar 3, 2021

Olympus eyes Medi-Tate acquisition

Laborie is set to exit the medical device manufacturer after another of its investors, Olympus, announced its intention to pay $260m for its remaining shares.

Mar 3, 2021

ACV Auctions aims for $100m in IPO

Online car dealership service ACV Auctions has filed to go public having previously raised some $360m in funding from investors including SoftBank.

Mar 3, 2021

Compass seeks $500m in initial public offering

SoftBank is the largest investor in the online real estate portal, which was valued at $6.4bn in its series G round early last year.

Mar 2, 2021

DigitalOcean swims towards initial public offering

Access Industries is set to exit the cloud infrastructure technology developer, which has filed to raise up to $100m on the New York Stock Exchange.

Mar 2, 2021

Connect Bio to attach itself to public markets

Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.

Mar 2, 2021

Cision to snag Brandwatch in $450m acquisition

Cision, already a shareholder in the social media analytics provider, is set to pay $450m to acquire it, following $63m in funding.

Mar 2, 2021

MDLive heads to Evernorth

Sutter Health, Novo, Sentara and Health Care Service Corporation are set to exit the virtual healthcare provider in an acquisition of undisclosed size.

Mar 2, 2021

Manbang Group loads up billion-dollar IPO

Tencent, SoftBank and Alphabet are in line for exits after the trucking services provider confidentially filed to float in a US initial public offering sized above $1bn.

Mar 1, 2021

AstraZeneca achieves Moderna stake sale

AstraZeneca likely received over $1bn from selling its shares, having invested $140m in the publicly listed covid-19 vaccine developer in 2015.

Mar 1, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here